Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CR-002 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on CR-002, a putative antibody-drug conjugate (ADC) targeting CD274 (PD-L1) (Nov 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CR-002 | CR002|CR 002 | PD-L1/PD-1 antibody 140 | Limited information is currently available on CR-002, a putative antibody-drug conjugate (ADC) targeting CD274 (PD-L1) (Nov 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07909031 | Phase Ib/II | CR-002 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (APOLLO) | Recruiting | USA | 0 |